<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458923</url>
  </required_header>
  <id_info>
    <org_study_id>Iyad Goussous</org_study_id>
    <nct_id>NCT03458923</nct_id>
  </id_info>
  <brief_title>Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.</brief_title>
  <official_title>Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the effect of intravitreal non steroidal anti inflammatory
      (Diclofenac) versus the standard treatment of diabetic macular edema, intravitreal anti
      vascular endothelial growth factor (Ranibizumab), measuring central macular thickness changes
      and best corrected visual acuity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty eyes of diabetic patients with diabetic retinopathy with macular edema will be
      randomized using simple randomization method into two groups; A and B.

      Group A will undergo intravitreal injection of 500µg Diclofenac, repeated monthly for 3
      months. Electroretinogram will be performed before the injections, 4 weeks after first
      injection and 4 weeks after third injection to assess any risk of toxicity.

      Colored photography and fundus fluorescein angiography will be done before the first
      injection to assess the extent of macular leakage at late phases, and to exclude cases with
      macular ischemia.

      Optical coherence tomography will be done to measure the central macular thickness, before
      the first injection, and before each injection.

      Visual acuity will be assessed before and after each injection.

      Group B will undergo intravitreal injection of 0.5 mg Ranibizumab, repeated monthly for 3
      months. Colored photography and fundus fluorescein angiography will be done before the first
      injection to assess the extent of macular leakage at late phases, and to exclude cases with
      macular ischemia.

      Optical coherence tomography will be done to measure the central macular thickness, before
      the first injection, and before each injection.

      Visual acuity will be assessed before and after each injection.

      All patients will be examined weekly for one month and then monthly for three months after
      the injection. At every visit, visual acuity, intraocular pressure, and a dilated fundus
      examination will be performed.

      All patients will be required to instill topical antibiotic Gatifloxacin postoperatively 3
      times per day for 5 days.

      Patients will be warned about the signs and symptoms of complications (endophthalmitis,
      retinal detachment, vitreous hemorrhage, lens trauma) and asked to seek medical attention
      immediately.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in best corrected visual acuity</measure>
    <time_frame>3 months of follow up</time_frame>
    <description>Measuring the best corrected visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in central macular thickness</measure>
    <time_frame>3 months of follow up</time_frame>
    <description>Measuring the change in central macular thickness using Optical Coherence Tomography</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 eyes will receive 0.1 ml containing 500µg of diclofenac intravitreally, repeated monthly for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 eyes will receive 0.5 mg Ranibizumab intravitreally, repeated monthly for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium 0.1 ml containing 500µg</intervention_name>
    <description>15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>nonsteroidal anti-inflammatory drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5 mg Solution for Injection</intervention_name>
    <description>15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>anti vascular endothelial growth factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diabetic retinopathy with non tractional maculopathy, where central macular thickness
             is greater than 400µm, with and without cystic changes.

          2. Diabetes Mellitus type one and two

          3. Best Corrected Visual Acuity &gt; 0.1 LogMar

        Exclusion Criteria:

          1. Patients treated with diclofenac, Ranibizumab or Bevacizumab in the past 3 months

          2. Patients with a history of branch or central retinal artery occlusion

          3. Patients without clear media and adequate pupillary dilation that allows proper
             fundoscopy and imaging, and patients who are not complaint with the regular visits.

          4. Visual Significant Cataract

          5. Evidence of vitreomacular traction or macular ischemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed S El Agha, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iyad A Goussous, MSc</last_name>
    <phone>00201062453343</phone>
    <email>dr.iyad.goussous@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed S El Agha, PhD</last_name>
      <phone>00201001638180</phone>
      <email>mselagha@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Iyad Adnan Salem Goussous</investigator_full_name>
    <investigator_title>Doctor Iyad Adnan Salem Goussous</investigator_title>
  </responsible_party>
  <keyword>Diclofenac</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

